Allergan Raises Profit Forecast as Valeant Pursues Bid
Profit in the third quarter will be $1.76 to $1.78 per share, above the company’s previous forecast of $1.44 to $1.47, the company said in a statement today. Earnings this year, next year and in 2016 will be higher than analysts are estimating, the Irvine, California-based company said...
Login to comment.